

AMENDMENT

Amendment To The Claims:

This listing of claims will replace all prior revisions, and listings, of claims in the application:

1. (Currently amended) A method of diagnosing an aggressive form of cancer, the method comprising steps of:

providing a genetic sample from a test sample of a tumor; and

analyzing expression of *Wnt5a* wherein increased expression of *Wnt5a* in the test sample compared to *Wnt5a* expression in a tumor having less than about 3.5% invasive ability indicates the tumor is aggressive and at least one gene selected from the group consisting of MART-1, p16, HADHB, CD63, ENDRB, PGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKF, synuclein a, annexin A2, CD20, and RAB2; and

~~identifying the tumor as aggressive or non-aggressive based on the expression pattern of the genes.~~

2. (Withdrawn) The method of claim 1, the method further comprising step of: selecting a treatment regimen for an individual with the tumor based on whether the tumor is aggressive or non-aggressive.

3. (Withdrawn) The method of claim 1, wherein the cancer is malignant melanoma.

4. (Currently Amended) A method of diagnosing an aggressive form of malignant melanoma, the method comprising steps of:

providing a genetic sample from a test sample of a tumor;

determining expression of *Wnt5a* wherein increased expression of *Wnt5a* in the test sample compared to *Wnt5a* expression in a tumor having non-detectable or no

vasculogenic mimicry indicates the tumor is aggressive;

~~identifying the tumor as aggressive or non-aggressive based on the
expression of Wnt5a; and~~

~~selecting a first treatment regimen for an individual with the tumor based on
whether if the tumor is aggressive and a second treatment regimen if the tumor is or
non-aggressive, wherein the first and second treatment regimens are not the same.~~

5-20. (Canceled)

21. (Withdrawn) A method of diagnosing an aggressive form of cancer, the
method comprising steps of:

providing a genetic sample from a test sample of a tumor;

analyzing expression of Wnt5a gene;

analyzing expression of at least one gene selected from the group
consisting of MART-1, pirin, HADHB, CD63, ENDRB, RGAM1, HXB, RXRA, integrin
b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2,
CD20, and RAB2; and

identifying the tumor as aggressive or non-aggressive based on the expression
pattern of the genes.

22. (Withdrawn) The method of claim 21, wherein the step of analyzing expression
of at least one gene comprises analyzing expression of at least two genes selected from the
group consisting of MART-1, pirin, HADHB, CD63, ENDRB, RGAM1, HXB, RXRA,
integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a,
annexin A2, CD20, and RAB2.

23. (Withdrawn) The method of claim 21, wherein the step of analyzing
expression of at least one gene comprises analyzing expression of at least three genes
selected from the group consisting of of MART-1, pirin, HADHB, CD63, ENDRB,

RGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2, CD20, and RAB2.

24. (Withdrawn) The method of claim 1, wherein the step of analyzing comprises analyzing expression of Wnt5a, of MART-1, pirin, HADHB, CD63, ENDRB, RGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2, CD20, and RAB2.

25. (Previously Added) The method of claim 4, wherein the cancer is malignant melanoma.